Quick Summary:
As the pressures of the global stage continue to evolve, a reactive approach to the burgeoning Narcolepsy Therapeutics Market is a formula for missed opportunities. Proactively anticipating and responding to market trends and movements is made possible with our comprehensive market research report. Valued at $2 billion USD in 2022, this expanding market is forecasted to reach $3.6 billion USD by 2030, offering significant potential for savvy business leaders.
Highlighting key players such as Arena Pharmaceuticals, Jazz Pharmaceuticals PLC and Teva Pharmaceutical Industries Ltd, our meticulously detailed report includes a dedicated segment on the growth trajectory of Narcolepsy without Cataplexy. It further explores regional market dynamics, with noteworthy deep-dives into the U.S., China, Japan and Canada among others. Leverage this diligently compiled knowledge, for staying ahead of the curve in the realm of Narcolepsy Therapeutics.
Global Narcolepsy Therapeutics Market to Reach $3.6 Billion by 2030
The global market for Narcolepsy Therapeutics estimated at US$2 Billion in the year 2022, is projected to reach a revised size of US$3.6 Billion by 2030, growing at a CAGR of 7.3% over the analysis period 2022-2030. Narcolepsy with Cataplexy, one of the segments analyzed in the report, is projected to record a 7% CAGR and reach US$1.9 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Narcolepsy without Cataplexy segment is readjusted to a revised 8.2% CAGR for the next 8-year period.
The U.S. Market is Estimated at $558.1 Million, While China is Forecast to Grow at 11.7% CAGR
The Narcolepsy Therapeutics market in the U.S. is estimated at US$558.1 Million in the year 2022. China, the world's second largest economy, is forecast to reach a projected market size of US$833.8 Million by the year 2030 trailing a CAGR of 11.7% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 2.9% and 7.5% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 4.3% CAGR. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$503.2 Million by the year 2030.Select Competitors (Total 14 Featured) -
- Arena Pharmaceuticals, Inc.
- BioProjet Pharma
- Graymark Healthcare, Inc.
- Jazz Pharmaceuticals PLC
- Ligand Pharmaceuticals, Inc.
- Shionogi, Inc.
- Shire PLC
- Teva Pharmaceutical Industries Ltd.
What's New?
- Special coverage on Russia-Ukraine war; global inflation; easing of zero-Covid policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.
- Global competitiveness and key competitor percentage market shares
- Market presence across multiple geographies - Strong/Active/Niche/Trivial
- Online interactive peer-to-peer collaborative bespoke updates
- Access to digital archives and Research Platform
- Complimentary updates for one year
What is the estimated value of the Global Market for Narcolepsy Therapeutics?
What is the growth rate of the Global Market for Narcolepsy Therapeutics?
What is the forecasted size of the Global Market for Narcolepsy Therapeutics?
Who are the key companies in the Global Market for Narcolepsy Therapeutics?
| Report Attribute | Details |
|---|---|
| No. of Pages | 363 |
| Published | November 2023 |
| Forecast Period | 2022 - 2030 |
| Estimated Market Value ( USD | $ 2 Billion |
| Forecasted Market Value ( USD | $ 3.6 Billion |
| Compound Annual Growth Rate | 7.6% |
| Regions Covered | Global |
Table of Contents
Companies Mentioned
A selection of companies mentioned in this report includes:
- Arena Pharmaceuticals, Inc.
- BioProjet Pharma
- Graymark Healthcare, Inc.
- Jazz Pharmaceuticals PLC
- Ligand Pharmaceuticals, Inc.
- Shionogi, Inc.
- Shire PLC
- Teva Pharmaceutical Industries Ltd.
